Royalty Pharma plc (RPRX)

Market Cap	16.40B
Revenue (ttm)	2.32B
Net Income (ttm)	184.41M
Shares Out	599.59M
EPS (ttm)	0.38
PE Ratio	71.97
Forward PE	6.98
Dividend	$0.80 (2.93%)
Ex-Dividend Date	Nov 16, 2023

Volume	1,275
Open	27.07
Previous Close	27.07
Day's Range	26.84 - 27.36
52-Week Range	25.92 - 44.21
Beta	0.42
Analysts	Strong Buy
Price Target	55.00 (+101.1%)
Earnings Date	Nov 8, 2023

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX

Financial Performance

In 2022, Royalty Pharma's revenue was $2.24 billion, a decrease of -2.28% compared to the previous year's $2.29 billion. Earnings were $42.83 million, a decrease of -93.09%.

Analyst Forecast

According to 3 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $55.0, which is an increase of 101.10% from the latest price.

Price Target

$55.0

(101.10% upside)

Analyst Consensus: Strong Buy